Clinical Trial Details
| Trial ID: | L3252 |
| Source ID: | NCT00404963 |
| Associated Drug: | Placebo |
| Title: | A Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Type 2 Diabetes Mellitus |
| Interventions: | DRUG: placebo|DRUG: GSK376501 |
| Outcome Measures: | Primary: Safety will be monitored by assessing adverse reactions,changes in laboratory values (hematology, clinical chemistry, urinalysis),changes in vital signs (oral body temperature,60 second respiratory rate, blood pressure and heart rate), and ECG changes., throughout the study | Secondary: Blood levels of GSK376501 Effects of GSK376501 on the body, by measuring changes in insulin, glucose, and other markers, throughout the study |
| Sponsor/Collaborators: | Sponsor: GlaxoSmithKline |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE1 |
| Enrollment: | 72 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: SINGLE|Primary Purpose: DIAGNOSTIC |
| Start Date: | 2006-10 |
| Completion Date: | 2007-05 |
| Results First Posted: | |
| Last Update Posted: | 2017-01-19 |
| Locations: | GSK Investigational Site, Evansville, Indiana, 47714, United States |
| URL: | https://clinicaltrials.gov/show/NCT00404963 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|